TY - JOUR
T1 - Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma
T2 - An Eastern Cooperative Oncology Group study (PA482)
AU - Wiernik, Peter H.
AU - Phillips, Vincent
AU - Camacho, Fernando J.
AU - Oken, Martin M.
AU - O'Connell, Michael J.
N1 - Funding Information:
This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair) and supported in part by Public Health Service grants CA14958, CA20365, CA136.50, and CA21115 from the National Cancer Institute, National Institutes of Health and the Department of Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
PY - 1998
Y1 - 1998
N2 - A new regimen not cross-resistant with standard regimens was developed for patients with relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma. The regimen consisted of cisplatin, 70 mg/M2 given intravenously on day 1, vindesine, 3 mg/M2 given intravenously on days 1 and 8 (and also on day 15 of the first cycle only), and methylguazone, 600 mg/M2 given intravenously on days 8 and 15. Courses were repeated every 21 days. Thirty-nine patients (35 with non-Hodgkin's and 4 with Hodgkin's lymphoma) were treated and all were evaluable for response and toxicity. There were 5 complete and 14 partial responses for a total response rate of 49% (C.I. = 35%-63%). The median durations of partial and complete response were only 2.8 and 4.2 months, respectively. Only one patient remained in complete response for more than a year. There was one treatment-related death from renal failure on the study. Although this regimen was, in general, well tolerated the results are disappointing and seem no better than those obtained with many other salvage regimens for lymphoma.
AB - A new regimen not cross-resistant with standard regimens was developed for patients with relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma. The regimen consisted of cisplatin, 70 mg/M2 given intravenously on day 1, vindesine, 3 mg/M2 given intravenously on days 1 and 8 (and also on day 15 of the first cycle only), and methylguazone, 600 mg/M2 given intravenously on days 8 and 15. Courses were repeated every 21 days. Thirty-nine patients (35 with non-Hodgkin's and 4 with Hodgkin's lymphoma) were treated and all were evaluable for response and toxicity. There were 5 complete and 14 partial responses for a total response rate of 49% (C.I. = 35%-63%). The median durations of partial and complete response were only 2.8 and 4.2 months, respectively. Only one patient remained in complete response for more than a year. There was one treatment-related death from renal failure on the study. Although this regimen was, in general, well tolerated the results are disappointing and seem no better than those obtained with many other salvage regimens for lymphoma.
KW - Cisplatin
KW - Hodgkin's disease
KW - Lymphoma
KW - Methylguazone
KW - Vindesine
UR - http://www.scopus.com/inward/record.url?scp=0031873589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031873589&partnerID=8YFLogxK
U2 - 10.3109/10428199809057574
DO - 10.3109/10428199809057574
M3 - Article
C2 - 9711924
AN - SCOPUS:0031873589
SN - 1042-8194
VL - 30
SP - 619
EP - 624
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5-6
ER -